Preferred regimens of NAC for HER2-negative breast cancer are dose-dense adriamycin and cytoxan followed by paclitaxel or weekly paclitaxel, and those for HER2-positive breast cancer are paclitaxel + trastuzumab, paclitaxel + carboplatin + trastuzumab (TCH), and TCH + pertuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.